T. Rowe Price Associates
PAVM icon

T. Rowe Price Associates’s PAVmed PAVM Stock Holding History

T. Rowe Price Associates’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55
Closed -$61K – 3012
2021
Q4 		$61K Sell
55
-3
-5% -$6.52K ﹤0.01% 2916
2021
Q3 		$223K Sell
58
-1
-2% -$3.15K ﹤0.01% 2683
2021
Q2 		$171K Sell
59
-82
-58% -$194K ﹤0.01% 2763
2021
Q1 		$282K Buy
+141
New +$212K ﹤0.01% 2587

Other funds holding PAVM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's PAVM Position: Q1 2022 in Review

T. Rowe Price Associates sold out of PAVmed (PAVM) in Q1 2022, closing a stake of 55 shares — an estimated $61K sold.

T. Rowe Price Associates first reported a position in PAVM in Q1 2021 and held it in 4 quarters. The position peaked at $282K in Q1 2021. 94 funds tracked by Wall St. Rank hold PAVM as of Q1 2022.

  • T. Rowe Price Associates reported no remaining PAVmed position as of Q1 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 55 PAVmed shares in Q1 2022, an estimated $61K.
  • T. Rowe Price Associates first reported a position in PAVmed in Q1 2021 and held it in 4 quarters.
  • T. Rowe Price Associates's PAVmed position peaked at $282K in Q1 2021.
  • 94 funds tracked by Wall St. Rank held PAVmed as of Q1 2022.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.